<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194684</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2129</org_study_id>
    <nct_id>NCT04194684</nct_id>
  </id_info>
  <brief_title>Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer</brief_title>
  <official_title>Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer：a Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the
      therapy ER+/HER2- recurrent metastatic breast cancer。
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 28, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Estimated up to 1 year</time_frame>
    <description>Defined as proportion of complete response and partial response according to RECIST 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>CR+PR+SD≥8 weeks</time_frame>
    <description>Defined as proportion of complete response 、partial response and stable disease according to RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Estimated up to 2 year</time_frame>
    <description>Calculated from the time the study drug was first administered to the first confirmation of disease progression or death (whichever occurs first)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Assigned Interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.</description>
    <arm_group_label>Assigned Interventions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, 18 to 70 years old;

          2. histologically confirmed recurrent or metastatic breast cancer, ER-positive (&gt; 10%),
             HER-2 negative (Definition: immunohistochemical [IHC] 0, 1+, or in situ hybridization
             [ISH] negative It is defined as the ratio of HER2 gene copy number to the number of
             CEP17 signals is less than 2.0, or for single probe detection, the HER2 gene copy
             number is less than 6);

          3. After transfer, ≤2 lines and ≥1 line endocrine therapy, and progress;

          4. at least one measurable lesion according to RECIST 1.1 ;

          5. ECOG score≤2;

          6. Expected survival≥3 months;

          7. Bone marrow function: white blood cells≥3×109/L, neutrophils≥1.5×109/L, platelets
             ≥100×109 / L, hemoglobin≥90g / L;

          8. Liver and kidney function: total bilirubin (TBIL) ≤1.5 times the upper limit of normal
             value, alanine aminotransferase (ALT), aspartate aminotransferase (AST) are ≤2.5 times
             the upper limit of normal value; if due to liver metastasis, the above indicators ≤5
             times the upper limit of normal value; serum creatinine (Cr) ≤1.5 times the upper
             limit of normal value;

          9. taxane adjuvant chemotherapy for more than 1 year;

         10. Women of childbearing age have a negative pregnancy test and must agree to take
             effective contraceptive measures during the study and within 3 months after the last
             dose

         11. Sign written informed consent before the test.

        Exclusion Criteria:

          1. Received chemotherapy after transfer;

          2. Patients with congestive heart failure with a grade II or above identified by the New
             York Heart Association (NYHA) score;

          3. Uncontrolled brain metastases;

          4. Severe systemic infections;

          5. Peripheral neuropathy of degree II or above within 4 weeks before enrollment, or
             patients known to be allergic or intolerant to this drug;

          6. Important organ diseases:liver and kidney dysfunction, history of myocardial
             infarction, unstable heart disease, chronic active hepatitis, etc .;

          7. History of other malignant tumors within 5 years (except cured cervical cancer or skin
             basal cell carcinoma);

          8. Received other anti-tumor treatments or other experimental drugs within 1 month before
             starting treatment;

          9. Patients participating in other clinical trials at the same time;

         10. Any medical condition in which the investigator considers the patient unsuitable for
             study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Yuan</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Yuan</last_name>
    <phone>+8613501270834</phone>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Peng Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

